

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**





DL

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> <b>A61K 9/16, 47/48</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 97/39738</b> <b>(43) International Publication Date:</b> 30 October 1997 (30.10.97)
<b>(21) International Application Number:</b> PCT/IE97/00030 <b>(22) International Filing Date:</b> 22 April 1997 (22.04.97)  <b>(30) Priority Data:</b> 960308 23 April 1996 (23.04.96) IE  <b>(71) Applicant (for all designated States except US):</b> KINERTON LIMITED [IE/IE]; Blanchardstown Industrial Park, Blanchardstown, Dublin 15 (IE).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> IGNATIOUS, Francis [IN/US]; 2 Shadowbrook Lane #52, Milford, MA 01757 (US). LOUGHMAN, Thomas, Ciarán [IE/IE]; 63 Foxfield Avenue, Raheny, Dublin 5 (IE). SHALABY, Shalaby, W. [US/US]; 6309 Highway 187, Anderson, SC 29670 (US). TOURAUD, Franck, Jean-Claude [FR/FR]; Hameau de Normandie, 23, rue de la Vallée, F-27200 Vernon (FR).  <b>(74) Agent:</b> ANNE RYAN & CO.; 60 Northumberland Road, Ballsbridge, Dublin 4 (IE).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU. ARIPO patent (GH, KE, LS, MW, SD, SZ, UG). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> SUSTAINED RELEASE IONIC CONJUGATE  <b>(57) Abstract</b>  A method of spherifying a sustained release ionic conjugate which contains a free carboxyl group-containing biodegradable polymer and a free amino group-containing drug which are ionically bonded to each other.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## Description

### Sustained release ionic conjugate

#### Technical Field

5 This invention relates to sustained release drug delivery systems and, in particular, to a method of making microparticles of a sustained release ionic conjugate.

#### Background Art

10 Biodegradable polymeric drug delivery formulations have been developed and utilized for the controlled *in vivo* release of drugs. See, e.g., U.S. Patent Nos. 3,773,919 and 4,767,628. Such biodegradable polymeric formulations are designed to allow an entrapped drug to slowly diffuse through a polymer matrix or coating when the biodegradable polymer is depolymerized.

15 International Publication No. WO 94/15587 describes sustained release ionic molecular conjugates of polyesters and drugs. Since polyester degradation is a key step in the release process, the surface area of the conjugate particles can control the release profile of the drug from the conjugate. Thus, the conjugate particles should be of similar size and shape to insure both the minimum and reproducible  
20 surface area, e.g., microspheres.

#### Disclosure of Invention

25 In one aspect, this invention features a method of making microparticles of a sustained release ionic conjugate containing a free carboxyl group-containing biodegradable polymer (a polyester made of monomers such as lactic acid, e-caproic acid, glycolic acid, trimethylene carbonate, or p-dioxanone; or a copolymer thereof; the monomers can be optically isomers or racemates) and a free amino group-containing drug (e.g., a peptide drug such as somatostatin or

LHRH) which are ionically bonded to each other. The method includes the steps of (1) obtaining a first solution in which the conjugate is dissolved; (2) mixing the first solution (added as small droplets, e.g., through an atomizing nozzle such as sonic nozzle, pneumatic nozzle, rotary atomizer, or pressure nozzle) with a first liquid to form a first dispersion, wherein the first liquid is miscible with the first solution, and the conjugate is not soluble in the first liquid and precipitates out of the first dispersion; and (3) isolating the conjugate from the first dispersion.

10 In one embodiment, the drug is soluble in the first liquid, which can be an alcohol (e.g., ethanol or isopropyl alcohol), hexane, or water; or a mixture thereof. When ethanol is used as the first liquid, it can be maintained between about 0°C and -30°C when it is being used. When isopropyl alcohol is used, it can be maintained between about 0°C and  
15 -70°C, e.g., cooled by the addition of dry ice.

The first solution, which may contain acetone, dichloromethane, acetonitrile, ethyl acetate, tetrahydrofuran, or glyme, or mixtures thereof can be obtained by (1) dissolving the biodegradable polymer in a second liquid (e.g., acetone, tetrahydrofuran, glycone, ethyl acetate, methyl acetate, acetonitrile, ethyl formate, or glyme; or a mixture thereof) to form a second solution; (2) dissolving the drug in a third liquid (e.g., water or acetone; or a mixture thereof) to form a third solution, wherein the third liquid is miscible with the first liquid and the second liquid; and (3) mixing the second solution and the third solution to form the first solution, wherein the mixing causes the drug to ionically bond to the biodegradable polymer and form the conjugate in the first solution. The first solution may comprise up to 40% by weight of the conjugate (e.g., between 25 and 35 percent by weight of the conjugate). In one example, a base, e.g., NaOH or KOH, can be  
20 added to the second solution prior to mixing the second solution and the third solution. Neutralization of the carboxyl groups of the biodegradable polymer with the base facilitates the formation of the ionic conjugate.

Alternatively, the first solution is obtained by dissolving the biodegradable polymer and the drug in a second liquid (e.g., acetone or a mixture of acetone and water) to form the first solution, thereby forming the conjugate in the first solution. According to this method, the biodegradable polymer can be first dissolved in the second liquid, a base is then added to the second solution, and the drug is subsequently dissolved in the second liquid. Also, if desired, the first solution can be partially or completely evaporated from the first dispersion prior to isolation of the conjugate. The processed conjugate can be conveniently isolated by centrifuging or filtering the first dispersion, and the isolated conjugate can be mixed with an aqueous mannitol solution prior to vacuum drying (e.g., lyophilization). The isolated conjugate can be further shaped into a film or a rod. The isolated conjugate can also be spherified into microspheres of average diameter of 5 to 200  $\mu\text{m}$ , e.g., as described herein. By "spherification" or "spherifying" is meant the processing of a microparticle into a shape close to a sphere.

In another aspect, this invention features a method of spherifying a sustained release ionic conjugate as described above. The method includes the steps of (1) mixing the conjugate with a first liquid (e.g., an oil such as silicon oil, mineral oil, sesame oil, or a vegetable oil) to form a first dispersion, wherein the conjugate has the shape of a microparticle and is not soluble in the first liquid; (2) heating the first dispersion to a temperature greater than the  $T_g$  or  $T_m$  of the conjugate; (3) cooling the first dispersion below the  $T_g$  or  $T_m$  of the conjugate; (4) mixing the first dispersion with a second liquid (e.g., hexane, heptane, isopropyl myristate, or an alcohol such as ethanol or isopropyl alcohol) to form a second dispersion, wherein the second liquid is miscible with the first liquid and the conjugate is not soluble in the second liquid; and (5) isolating the conjugate from the second dispersion. The conjugate may have the shape of a microcapsule with an average diameter of between 5  $\mu\text{m}$  to 200  $\mu\text{m}$  prior to mixing with the first liquid, and the first dispersion thus formed is vigorously stirred while being heated to aid in the separation of the particles. Once the conjugate has been isolated, it can be rinsed with the second

liquid and then vacuum dried. Optionally, it can also be mixed with an aqueous mannitol solution prior to vacuum drying.

A third aspect of this invention features a method of spherifying the above-described sustained release ionic conjugate (e.g., a  
5 microcapsule having an average diameter of between 5  $\mu\text{m}$  to 200  $\mu\text{m}$ ). The method includes the steps of (1) mixing the conjugate in a first liquid (e.g., water) to form a first dispersion, wherein the conjugate is in the shape of a microparticle and the conjugate is not soluble in the first liquid; (2) stirring the first dispersion; (3) mixing the stirred  
10 dispersion with a second liquid (e.g., dichloromethane or chloroform) in such an amount so that it is absorbed by the conjugate but does not solubilize the conjugate, wherein the second liquid is miscible with the first liquid; (4) evaporating the second liquid from the first dispersion; and (5) isolating the precipitated conjugate from the first dispersion. If  
15 necessary, the method may further include the step of adding a surfactant (e.g., lecithin, Tween 20, polysorbate, or lauryl sulfate) to the first dispersion to aid in the stabilization of the first dispersion, and the isolated conjugate can be rinsed with the first liquid and vacuum  
20 dried. Again, the isolated conjugate can be mixed with an aqueous mannitol solution prior to vacuum drying.

In a further aspect of this invention, this invention features a method of spherifying the above-described sustained release ionic conjugate. The method includes the steps of (1) dissolving the conjugate in a first liquid (e.g., acetonitrile) to form a first solution; (2)  
25 stirring the first solution with a second liquid (e.g., an oil) to form a first dispersion, wherein the second liquid is immiscible with the first solution; (3) evaporating the first liquid from the first dispersion to precipitate the conjugate from the first dispersion; and (4) isolating the precipitate conjugate from the first dispersion. In the stirring step, the  
30 first solution can be added to the second liquid as small droplets.

The above method can further include the step of rinsing the isolated conjugate with a third liquid (e.g., hexane, heptane, or octane) which is miscible with the second liquid and not a solvent for the



isolated conjugate. If desired, the isolated conjugate can be mixed with an aqueous mannitol solution prior to vacuum drying.

The biodegradable polymer in the above-described conjugate may contain at least one free carboxyl group (e.g., two to ten free carboxyl groups per polymer chain). Examples of carboxylic acid containing biodegradable polymers include polyesters containing units of lactic acid,  $\epsilon$ -caprolic acid, p-dioxanone,  $\epsilon$ -caprionic acid, substituted and unsubstituted trimethylene carbonate, 1,5-dioxepan-2-one, 1,4-dioxepan-2-one, glycolic acid, alkylene oxylate, cycloalkylene, cycloalkylene oxylate, alkylene succinate, or 3-hydroxy butyrate in optically active forms or as racemates; or copolymers of any of the above. Additional free carboxylic acid groups can be incorporated into the biodegradable polyester by reaction, e.g., ring opening polymerization or polycondensation, with polycarboxylic acids such as malic acid, tartaric acid, pamoic acid, citric acid, succinic anhydride, and glutaric anhydride. Thus, the biodegradable polymer can be a water insoluble polyester including lactic acid units with or without glycolic acid units. Other biodegradable polymers such as polyorthoesters, polyorthocarbonates, and polyantals may also be used. The biodegradable polymer may have an average degree of polymerization, e.g., average number of monomers per polymer chain, between 10 and 300.

The drug has one or more (e.g., one to ten) free amine groups. In one embodiment, the drug is an acid-stable peptide. Examples of suitable acid-stable peptides include growth hormone releasing peptide (GHRP), luteinizing hormone-releasing hormone (LHRH), adrenomedullin, growth hormone, somatostatin, bombesin, gastrin releasing peptide (GRP), calcitonin, bradykinin, galanin, melanocyte stimulating hormone (MSH), growth hormone releasing factor (GRF), amylin, adrenomedullin, tachykinins, secretin, parathyroid hormone (PTH), enkephalin, endothelin, calcitonin gene releasing peptide (CGRP), neuromedins, parathyroid hormone related protein (PTHrP), glucagon, neurotensin, adrenocorticotrophic hormone (ACTH), peptide YY (PYY), glucagon releasing peptide (GLP), vasoactive intestinal

peptide (VIP), pituitary adenylated cyclase activating peptide (PACAP), motilin, substance P, neuropeptide Y (NPY), TSH, and analogs and fragments thereof. The drug may be soluble (e.g., greater than 0.1 mg/ml; preferably, greater than 1.0 mg/ml) in the first liquid.

5 Other features and advantages of the present invention will be apparent from the detailed description and from the claims.

It is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. The following specific embodiments are, therefore, to be construed as  
10 merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Also, all  
15 publications, patent applications, patents, and other references mentioned herein are incorporated by reference.

### Best Modes for Carrying Out the Invention

#### Example 1

18.0 g of a 6,000 g/mol 66/32/2 poly-L-lactic-co-glycolic-co-  
20 D,L-malic acid copolymer (66 percent L-lactic acid, 32 percent glycolic, and 2 percent malic acid; acid number of 0.373 milliequivalents/g) was dissolved in 180 g of acetone (solution of 10% copolymer by weight). 14.4 ml of 0.5 N aqueous NaOH was added to form the sodium carboxylate of the polymer. 4.28 g of the acetate salt  
25 of the peptide Lanreotide™ (Kinerton, Dublin, Ireland; D-Nal-c[Cys-Tyr-D-Trp-Val-Cys]-Thr-NH<sub>2</sub>; acetate content = 9.60 percent by weight) was separately dissolved in a mixture of 10 g of acetone and 10 g of deionized water. The amount of peptide dissolved corresponded to the stoichiometric ratio of acid groups from the copolymer (e.g., one)  
30 and the free amino groups for the peptide (e.g., two). The peptide

solution was then added dropwise to the copolymer solution, and the resulting solution was stirred for two hours to allow for salt exchange and the resulting formation of the polymer/peptide ionic conjugate (PPIC).

5

### Example 2

In a temperature controlled jacketed reactor (Schott Glass AGB, Dublin, Ireland), a two liter bath of deionized water was precooled to 0°C and was vigorously stirred. The above PPIC solution of Example 1 was then slowly added to the reactor using a Masterflex pump (Bioblock Scientific, Illkuvch, France) which produced a flow rate of 10-15 ml/min through a silicone tubing fitted with a 19 gauge needle at its tip. The PPIC solution was fed through the needle that was positioned above a water bath at 0°C. The PPIC precipitated in the bath as small, solid particles. The solid particles were then separated from the supernatant by centrifugation (30 minutes at 5000 rpm and 0-5°C), rinsed with fresh deionized water, resuspended water, recentrifuged, and then lyophilized. The isolated conjugate was filtered through a 100 µm sieve to remove any large particles which would not be capable of being injected through a 21 gauge needle. An analysis of the resulting particle sizes is described in Table I.

20

### Example 3

The PPIC solution of Example 1 was also precipitated as described above in Example 2, except that a bath of ethanol at a temperature of -20°C was used instead of a bath of water at 0°C. An analysis of the resulting particle sizes is described in Table I.

25

### Example 4

The PPIC solution of Example 1 was also dispersed at a controlled flow rate of 4 ml/min through an atomizing nozzle containing a hollow tip (Bioblock; 50 Watts, 20 kHz) over a bath of ethanol at -10°C in a temperature controlled jacket reactor. In this

30

nebulization process, the copolymer solution was released from the probe as a fine mist of small droplets. The small droplets fell into the ethanol bath, causing the deionized water and acetone to be extracted from the droplets. As a result, the copolymer droplets hardened as small, solid particles. The particles were then recovered by centrifugation and lyophilized. An analysis of the resulting particle sizes is listed in Table I. What is meant by Diameter -10 (i.e., D0.1), Diameter -50 (i.e., D0.5), or Diameter -90 (i.e., D0.9) is the smallest diameter which is greater than 10%, 50%, and 90% of the total particles, respectively. What is meant by specific area is the average specific area of the resulting particles.

TABLE I

		Diameter-10	Diameter-50	Diameter-90	Specific Area
15	Example	( $\mu\text{m}$ )	( $\mu\text{m}$ )	( $\mu\text{m}$ )	( $\text{m}^2/\text{g}$ )
	2	10	30	62	18.64
	3	9	37	89	6.42
	4	13	46	95	22.61

20

Example 5

5.0 g of the PPIC described above in Example 4 was dissolved in 20 g of acetone (concentration of 20% PPIC by weight). This solution was then nebulized at a flow rate of 4.0 ml/min over 500 ml of bath of ethanol at  $-10^\circ\text{C}$  as described in Example 4. After preparation of the PPIC particles in the bath, 500 ml of deionized water was added to the bath, and the bath was then brought up to  $0^\circ\text{C}$ . The bath was then stirred for 30 min, brought up to  $20^\circ\text{C}$ , and stirred for an additional 30 min. The PPIC particles were then recovered by filtration and dried under vacuum at room temperature. An analysis of the resulting particles is listed in Table II.

TABLE II

	Example	D 0.1 ( $\mu\text{m}$ )	D 0.5 ( $\mu\text{m}$ )	D 0.9 ( $\mu\text{m}$ )	Specific Area ( $\text{m}^2/\text{g}$ )
5	#4	13	46	95	22.61
	#5	50	99	180	0.11

10 As shown in Table II, different morphologies of particles were obtained. The particles of Example 4 were larger and had a lower specific area. As indicated by electron scanning microscope, the particles obtained in Example 4 were also more porous, likely because of the frozen water which remained in the particles upon precipitation. When the bath dispersion was returned to room temperature, the water  
15 thawed and flowed into the ethanol bath, leaving open channels in the microparticles. Consequently, these particles were more brittle and generated fragments of small size.

Example 6

20 A solution of PPIC described above in Example 5 was nebulized at 2.5 ml/min over 1.5 liters of deionized water at 0°C. An analysis of the resulting particle sizes is listed in Table III.

Example 7

25 A solution of PPIC described above in Example 5 was nebulized at 2.5 ml/min over 1.5 liters of ethanol at -10°C. An analysis of the resulting particle sizes is listed in Table III.

TABLE III

5	Example	D 0.1	D 0.5	D 0.9	Specific Area
		( $\mu\text{m}$ )	( $\mu\text{m}$ )	( $\mu\text{m}$ )	( $\text{m}^2/\text{g}$ )
	6	53.4	154.3	329.1	n/a
	7	42.4	87.2	170.1	0.20

Example 8

10 Two solutions of PPIC are prepared in acetone as described above in Example 5. The first solution has a PPIC concentration of 15% while the second solution has a PPIC concentration of 20%. The solutions are nebulized over a bath of ethanol at  $-10^\circ\text{C}$  at flow rates of 2.5, 3.5, and 5.0 ml/min as described in Example 5. An analysis of the resulting particle size is listed in Table IV.

15

TABLE IV

20	Concentration	Feeding Rate	D 0.1	D 0.5	D 0.9	Specific Area
		(ml/min)	( $\mu\text{m}$ )	( $\mu\text{m}$ )	( $\mu\text{m}$ )	( $\text{m}^2/\text{g}$ )
	15%	2.5	35.9	81.6	191.1	4.455
	15%	3.5	34.4	80.2	188.3	8.336
	15%	5.0	49.4	163.6	397.8	n/a
	20%	2.5	33.3	73.8	145.6	0.199
25	20%	3.5	50.8	112.7	241.9	0.579
	20%	5.0	108.3	219.1	395.9	n/a

30 Analysis of the particles using scanning electron microscope revealed that the particle size and the specific area increased with the increase in feeding rate.

Example 9

5.0 g of PPIC microparticles of Example 4 was dissolved in 45 g of acetone (concentration 10% by weight). The solution was then added dropwise over a vigorously stirred 500 ml n-hexane at room temperature. The n-hexane solution turned cloudy as particles of PPIC precipitated. The PPIC was removed by filtration and dried under vacuum at room temperature.

Example 10

In a jacketed reactor, 3.0 g of the PPIC microparticles described in Example 2 was dispersed in a vigorously stirred 250 ml of 12,500 cs medical grade silicon oil (Dow Corning, Midland, MI) (of 1% PPIC by weight). After the stirring, the mixture was then heated to 120°C, which is above the T<sub>g</sub> of 55°C for the PPIC, and kept at this temperature for 30 minutes. During this heating, the isolated individual particles melted to form spherical droplets. The dispersion was then cooled to 20°C and then diluted with 1250 ml of hexane. The microspheres subsequently hardened, were recovered by filtration, were rinsed with fresh hexane, and were finally dried under vacuum. The characteristics of the obtained microspheres are reported in Table V. The final microspheres had a small diameter as compared to those of Example 2 as a result of the compaction of the particles during melting.

TABLE V

Example	D 0.1 ( $\mu\text{m}$ )	D 0.5 ( $\mu\text{m}$ )	D 0.9 ( $\mu\text{m}$ )	Specific Area ( $\text{m}^2/\text{g}$ )
#2	10	30	62	18.64
#7	2	10	47	<0.33

Example 11

0.2 g of the PPIC microparticles described in Example 2 were dispersed in 5 ml of deionized water and vigorously stirred with a vortex shaker. 100  $\mu$ l of dichloromethane (DCM) was then added over the stirred dispersion. The addition of a small amount of DCM caused a swelling of the surface of the PPIC particles. Stirring was kept at room temperature for 4 hours, allowing for evaporation of DCM and consequential hardening of the swollen surface of the particles. A scanning electron microscope showed that the resulting particles were of spherical shape with a smoother surface as compared to the starting material. Both the particle size distribution was narrowed, and the maximum particle size was reduced as a result of the increase in the density of the particles.

Example 12

One liter of sesame seed oil (Vitamins, Inc., Chicago, IL) was placed in a 2 liter, three necked flask immersed in a water bath. The oil was stirred at 600 rpm using a teflon stirring paddle connected to an overhead stirring motor. 500 mg of the surfactant, soybean lecithin, (Sigma Chemicals, St. Louis, MO) was added to the sesame seed oil, and the mixture was stirred for 10 min. 10 g of a PPIC formulation was then dissolved in 100 ml acetonitrile to give a clear solution. The PPIC compositions were made using Lanreotide™ conjugated with one of the following three polymers: 64/34/2 poly-DL-lactic-co-glycolic-D,L-malic acid copolymer (M.W. avg 6,000) (Composition 1); 74/24/2 poly-DL-lactic-co-glycolic-D,L-malic acid copolymer (M.W. avg 6,000) (Composition 2); and 98/2 poly-DL-lactic-co-D,L-malic acid copolymer (Composition 3).

This clear PPIC solution was added dropwise through a dropping funnel. When the addition was completed, the temperature of the external water bath was raised to 40°C, and the oil was left stirring for 20 h. One liter of hexane was then added to dilute the sesame seed oil,



and the oil was filtered through a medium fritted funnel. The microspheres collected in the filter funnel were further washed several times with 500 ml in total volume of hexane. The particles are dried at 36°C for two days under vacuum. Characteristics of the resulting microspheres are presented in Table VI.

TABLE VI

	Composition	D 0.1 ( $\mu\text{m}$ )	D 0.5 ( $\mu\text{m}$ )	D 0.9 ( $\mu\text{m}$ )	Specific Area ( $\text{m}^2/\text{g}$ )
10	1	13	28	57	0.1426
	2	13	25	59	0.1395
15	3	14	25	51	0.1480

Example 13

Reactor was loaded with monomers glycolide (Purac Biochem, Netherlands, 84.83 g), lactide (Purac Biochem, Netherlands, 210.67 g) and L(+)-tartaric acid (Riedel-de Haen, Seelze, Germany, article number 33,801, 4.50 g) and stannous 2-ethyl hexanoate (Sigma, St. Louis, Missouri, USA, article number S-3252) in toluene (Riedel-de Haen, Seelze, Germany) solution (0.1025 M, 4.34 ml). The L(+)-tartaric acid was previously dried over phosphorous pentoxide (Riedel-de Haen, Seelze, Germany) in an Abderhalden drying apparatus for 10 hours. The reactor (connected to pump *via* a liquid nitrogen trap) was then put under vacuum (0.04 mbar) with stirring for 50 minutes to remove toluene. The reactor, under an atmosphere of oxygen-free nitrogen (BOC gases, Dublin, Ireland, moisture content of 8 VPM), was then immersed in an oil bath (Temperature = 200°C) and stirring was increased to 125 rpm. Prior to immersion, a heating tape (Thermolyne type 45500, input control setting = 4) was placed on the

reactor lid. The time taken to completely melt the reactor contents was noted, typically 10 minutes for a load of 300 g at 200°C. Samples were taken every hour during synthesis and analyzed by GPC to determine the percentage residual monomer and to obtain values for average molecular weight by number (Mn) and by weight (Mw). Typical reaction times are of the order of 6 hours.

An amorphous copolymer was obtained comprising 66.21% lactide units, 33.11% glycolide units, and 0.68% tartaric acid units (66/33/1 PLGTA). The acid number of the titration was determined to 0.303 milliequivalents/g (meq/g; the normality of NaOH multiplied by the volume of NaOH solution required to neutralize one gram of polyester). The average number average molecular weight of the copolymer had a value of 10,250, the average weight molecular weight of the copolymer was 11,910 giving a Mw/Mn value of 1.16.

41.32 g of the above 10,000 g/mol 66/32/2 poly-L-lactic-co-glycolic-co-L(+)-tartaric acid copolymer (acid number = 0.303 meq/g) was dissolved in 165.52 g of acetone (Riedel-de Haen, Seelze, Germany) by sonication in a Branson sonication bath (Branson, Danbury, Connecticut, USA) to give a solution with a concentration of 19.98% PLGTA by weight.

To this solution was added 37.6 ml 0.2 N sodium carbonate (Aldrich, Gillingham, Dorset, UK) thus providing a 1.2 times excess of sodium over copolymer carboxyl groups. The solution was left to stir for 30 minutes to aid sodium salt formation. It was then fed to an atomizer nozzle at 8.0 ml/min using a Masterflex pump (Cole Parmer, Barrington, Illinois, USA). The solution was nebulized into a 6 L jacketed reactor containing 2 L of de-ionized water cooled to 2.5°C using a circulation bath (Huber, Offenburg, Germany). This water was stirred to 350 rpm using a 4-blade paddle linked to a stirrer motor.

Once nebulization was complete, the dispersion was placed in 6 centrifuge bottles and spun at 5000 rpm for 30 minutes in a Sorvall centrifuge (DuPont Sorvall Products, Wilmington, Delaware, USA).

The resultant centrifuge cakes were resuspended in de-ionized water and re-spun. The supernatant was discarded and the cakes were frozen in a freezer overnight before being dried in a small-scale lyophilizer (Edwards, Crawley, West Sussex, UK) the next day. 33.16 g of washed  
5 copolymer were recovered representing a yield of 80.24%.

4.92 g of the above 10,000 g/mol 66/33/1 poly-L-lactic-co-glycolic-co-D,L-tartaric acid copolymer (66 percent L-lactic acid, 33 percent glycolic acid, and 1 percent tartaric acid) was dissolved in 11.58 g of acetonitrile (Ridel-de Haen, Seelze, Germany; HPLC grade)  
10 by sonication in a Branson sonication bath (Branson, Danbury, CT, USA) and stirred on a stir-plate producing a solution with a concentration of 29.82% of PLGTA by weight.

This copolymer/acetonitrile solution was fed from a glass reservoir through an atomizer nozzle using an FMI revolving piston pump (FMI, Oyster Bay, NY, USA) set at 2.0 ml/min. The atomizer  
15 output power was set at 50 W with an amplitude of 80%. The solution was nebulized into a 6L jacketed reactor containing 1.5 L of general purpose reagent isopropyl alcohol (Labscan, Dublin, Ireland), cooled to -70°C by solid CO<sub>2</sub> pellets (AIG, Dublin, Ireland), and stirred at 300  
20 rpm with a 4-blade paddle linked to a stirrer motor. The temperature of the isopropyl alcohol remained at or close to -70°C throughout nebulization which lasted for approximately 8 minutes.

Once nebulization was complete, the dispersion was allowed to warm to 10°C of its own accord over a period of 5.5 hours. It was  
25 then filtered over a Whatman No. 1 filter paper (9 cm diameter) with the aid of a vacuum. The filter paper and cake were placed in a desiccator along with silica gel drying chips and a vacuum was pulled through an automatic refrigeration trap at -110°C. After 24 hours 4.24 g of material were recovered. An analysis of the resulting particles is  
30 listed in Table VII.

TABLE VII

5	Example #	D 0.1	D 0.5	D 0.9	Specific Area
		( $\mu\text{m}$ )	( $\mu\text{m}$ )	( $\mu\text{m}$ )	( $\mu^2/\text{g}$ )
	13	31	68	139	0.16

10 It is to be understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the claims.

Claims:-

1. A method of making microparticles of a sustained release ionic conjugate containing a free carboxyl group-containing biodegradable polymer and a free amino group-containing drug which are ionically bonded to each other, the method comprising:
- 5 obtaining a first solution in which said conjugate is dissolved, wherein said solution comprises acetone, acetonitrile, ethyl acetate, tetrahydrofuran, or glyme;
- 10 mixing said first solution with a first liquid to form a first dispersion, wherein said first liquid is miscible with said first solution, and said conjugate is not soluble in said first liquid and precipitates out of said first dispersion; and
- isolating said conjugate from said first dispersion.
2. A method according to claim 1, wherein said first solution is added to said first liquid as small droplets.
- 15 3. A method according to claim 2, wherein said first solution is added to said first liquid through an atomizing nozzle.
4. A method according to any one of claims 1-3, wherein said drug is a peptide.
- 20 5. A method according to any preceding claim, wherein said biodegradable polymer is a polyester made of lactic acid, e-caprolic acid, glycolic acid, trimethylene carbonate, or p-dioxanone; or a copolymer thereof.
6. A method according to any preceding claim, wherein said drug is soluble in said first liquid.
- 25

7. A method according to any preceding claim, wherein said biodegradable polymer is a polyester comprising lactic acid, or glycolic acid; or a copolymer thereof.

5 8. A method according to claim 7, wherein said polyester further contains malic acid, tartaric acid, citric acid, succinic acid, or glutaric acid.

9. A method according to any one of claims 4-8, wherein said peptide is a somatostatin or LHRH.

10 10. A method according to any preceding claim, wherein said first liquid is alcohol or water; or a mixture thereof.

11. A method according to claim 10, wherein said first liquid is ethanol maintained between about 0°C and -30°C or isopropyl alcohol maintained between about 0°C and -70°C.

15 12. A method according to any preceding claim, wherein said first solution contains acetone or acetonitrile.

13. A method according to any preceding claim, wherein said first solution is obtained by:

dissolving said biodegradable polymer in a second liquid to form a second solution;

20 dissolving said drug in a third liquid to form a third solution, wherein said third liquid is miscible with said first liquid and said second liquid; and

25 mixing said second solution and said third solution to form said first solution, wherein said mixing causes said drug to ionically bond to said biodegradable polymer and form said conjugate in said first solution.

14. A method according to claim 13, wherein NaOH or KOH is added to the second solution prior to mixing said second solution and said third solution.

5 15. A method according to claim 13 or 14, wherein said second liquid is acetone; and said third liquid is water or acetone; or a mixture thereof.

10 16. A method according to any of claims 1-12, wherein said first solution is obtained by dissolving said biodegradable polymer and said drug in a second liquid to form said first solution, thereby forming said conjugate in said first solution.

17. A method according to claim 16, wherein said second liquid is acetone or a mixture of acetone and water.

15 18. A method according to claim 17, wherein said biodegradable polymer is first dissolved in said second liquid, a base is then added to said second solution, and said drug is subsequently dissolved in said second liquid.

19. A method according to any preceding claim, wherein said conjugate is isolated by centrifuging or filtering said first dispersion.

20 20. A method according to claim 19, wherein said first solution is partially or completely evaporated from said first dispersion prior to isolation of said conjugate.

21. A method according to claim 20, wherein said isolated conjugate is mixed with an aqueous mannitol solution prior to vacuum drying.

25 22. A method of spherifying a sustained release ionic conjugate comprising a biodegradable polymer containing a free carboxyl group-containing biodegradable polymer and a free amino group-containing drug which are ionically bonded to each other, said method comprising:

mixing said conjugate with a first liquid to form a first dispersion, wherein said conjugate has the shape of a microparticle and is not soluble in said first liquid;

5 heating said first dispersion to a temperature greater than the  $T_g$  or  $T_m$  of said conjugate;

cooling said first dispersion below the  $T_g$  or  $T_m$  of said conjugate;

10 mixing said first dispersion with a second liquid to form a second dispersion, wherein said second liquid is miscible with said first liquid and said conjugate is not soluble in said second liquid; and

isolating said conjugate from said second dispersion.

23. A method according to claim 22, wherein said conjugate has the shape of a microcapsule which has an average diameter of between 5  $\mu m$  to 200  $\mu m$  prior to mixing with said first liquid and said first dispersion is stirred prior to said heating or cooling.

24. A method according to claim 22 or 23, wherein said biodegradable polymer is a polyester made of lactic acid or glycolic acid; or a copolymer thereof.

25. A method according to any one of claims 22-24, wherein said drug is a peptide.

26. A method according to any one of claims 22-25, wherein said first liquid is an oil and said second liquid is hexane.

27. A method according to any one of claims 22-26, further comprising:

25 rinsing said isolated conjugate with said second liquid; and



vacuum drying said rinsed conjugate.

28. A method according to claim 27, wherein said isolated conjugate is mixed with an aqueous mannitol solution prior to vacuum drying.

5 29. A method of spherifying a sustained release ionic conjugate containing a free carboxyl group-containing biodegradable polymer and a free amino group-containing drug which are ionically bonded to each other, said method comprising:

dissolving said conjugate in a first liquid to form a first solution;

10 stirring said first solution with a second liquid to form a first dispersion, wherein said second liquid is immiscible with said first solution;

evaporating said first liquid from said first dispersion to precipitate said conjugate from said first dispersion; and

15 isolating said precipitate conjugate from said first dispersion.

30. A method according to claim 29, wherein said first solution is added to said second liquid as small droplets.

31. A method according to claim 29 or 30, wherein said first liquid is acetonitrile and said second liquid is an oil.

20 32. A method according to claim 31, wherein said oil is silicon oil, mineral oil, sesame oil, or a vegetable oil.

33. A method according to any one of claims 29-32, wherein said biodegradable polymer is a polyester comprising lactic acid or glycolic acid; or a copolymer thereof.

34. A method according to any one of claims 29-33, wherein said drug is a peptide.

5        35. A method according to any one of claims 29-34, further comprising rinsing said isolated conjugate with a third liquid which is miscible with said second liquid and not a solvent for said isolated conjugate.

36. A method according to claim 35, wherein said third liquid is hexane, heptane, or octane.

10       37. A method according to any one of claims 29-36, wherein said isolated conjugate is mixed with an aqueous mannitol solution prior to vacuum drying.

38. A method of making microparticles of a sustained release ionic conjugate, substantially as hereinbefore described and exemplified.

15       39. A method of spherifying a sustained release ionic conjugate, substantially as hereinbefore described and exemplified.

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>A61K 9/16, 47/48</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 97/39738</b> <b>(43) International Publication Date:</b> 30 October 1997 (30.10.97)
<b>(21) International Application Number:</b> PCT/IE97/00030 <b>(22) International Filing Date:</b> 22 April 1997 (22.04.97) <b>(30) Priority Data:</b> 960308 23 April 1996 (23.04.96) IE <b>(71) Applicant (for all designated States except US):</b> KINERTON LIMITED [IE/IE]; Blanchardstown Industrial Park, Blanchardstown, Dublin 15 (IE). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> IGNATIOUS, Francis [IN/US]; 2 Shadowbrook Lane #52, Milford, MA 01757 (US). LOUGHMAN, Thomas, Ciarán [IE/IE]; 63 Foxfield Avenue, Raheny, Dublin 5 (IE). SHALABY, Shalaby, W. [US/US]; 6309 Highway 187, Anderson, SC 29670 (US). TOURAUD, Franck, Jean-Claude [FR/FR]; Hameau de Normandie, 23, rue de la Vallée, F-27200 Vernon (FR). <b>(74) Agent:</b> ANNE RYAN & CO.; 60 Northumberland Road, Ballsbridge, Dublin 4 (IE).	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  <b>(88) Date of publication of the international search report:</b> 27 November 1997 (27.11.97)	
<b>(54) Title:</b> SUSTAINED RELEASE IONIC CONJUGATE  <b>(57) Abstract</b>  A method of spherifying a sustained release ionic conjugate which contains a free carboxyl group-containing biodegradable polymer and a free amino group-containing drug which are ionically bonded to each other.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

Int ional Application No  
PCT/IE 97/00030

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K9/16 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, Y	WO 93 17668 A (ALKERMES CONTROLLED THERAPEUTI) 16 September 1993  see the whole document	1-20, 22-25, 27, 29-39
X, Y	WO 94 15587 A (KINERTON LIMITED ; SHALABY SHALABY W (US); JACKSON STEVEN A (US); M) 21 July 1994 cited in the application	1, 2, 4-10, 12-20, 22-25, 27, 29, 30, 33-35, 38, 39
Y	see the whole document	3, 11, 31, 32, 36, 37
	---	
	- / - -	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*A\* document member of the same patent family

Date of the actual completion of the international search

1 October 1997

Date of mailing of the international search report

16. 10. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Fischer, W

# INTERNATIONAL SEARCH REPORT

Inte onal Application No  
PCT/IE 97/00030

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 556 917 A (AKZO NV) 25 August 1993  see the whole document ---	1-20, 22-25, 27,29-39
A	US 4 767 628 A (HUTCHINSON FRANCIS G) 30 August 1988 cited in the application ---	
A	US 3 773 919 A (BOSWELL G ET AL) 20 November 1973 cited in the application -----	